Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA study from ESMO23 on X/Twitter:
“Another big hit ESMO 23. Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT. Impressive curves and HR 0.24. Immediate practice-changing trial.”
Source: Julien Mazières/Twitter.
